NCT05878964View on ClinicalTrials.gov

Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.

RecruitingOBSERVATIONAL
Enrollment

420

Participants

Timeline

Start Date

May 22, 2023

Primary Completion Date

July 22, 2025

Study Completion Date

September 22, 2025

Conditions
Lung CancerBreast CancerKidney CancerBladder CancerGastric CancerSkin CancerMelanomaHead Neck Cancer
Interventions
OTHER

EQ-5D-5L questionnaire

Quality of life evaluation questionnaire

OTHER

FACT-G (Functional Assessment of Cancer Therapy - General)

Quality of life evaluation questionnaire

OTHER

FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)

Self reported evaluation of cutaneous toxicity questionnaire.

Trial Locations (1)

00168

RECRUITING

Roberto Iacovelli, Roma

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER